铁泽帕提德 (tirzepatide) 需要GIPR来从人类小岛分泌荷尔蒙
Kimberley El1, Jonathan D Douros2, Francis S Willard3
1Duke Molecular Physiology Institute, Durham, NC, USA.
Nature metabolism
|June 5, 2023
概括
蒂尔泽帕提德是一种双GIP/GLP-1受体激动剂,通过这两种受体刺激人类小岛的胰岛素分泌,与GLP-1R占主导地位的小鼠不同. 这种双重作用是其在糖尿病和肥胖症治疗效益的关键.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 像GIP和GLP-1这样的胰岛素抑制剂调节了依赖于葡萄糖的胰岛素分泌.
- GLP-1受体激动剂是糖尿病和肥胖症的确立治疗方法.
- 目前正在研究GIP受体激素的治疗作用.
研究的目的:
- 研究GIP和GLP-1受体对蒂尔泽帕提德对人类小岛激素分泌的作用的贡献.
- 为了比较tirzepatide在小鼠和人类岛屿中的作用机制.
主要方法:
- 研究了孤立的小鼠和人类小岛的胰岛素分泌.
- 利用GIP受体对抗性来评估其在蒂尔泽帕提德效应中的作用.
- 测量了胰岛素,葡萄糖和体静止素的分泌.
主要成果:
- 蒂尔泽帕提德主要在小鼠岛屿中激活GLP-1R,这是由于小鼠GIPR的效力较低.
- 在人类小岛上,阻断GIPR显著降低了铁泽帕提德诱导的胰岛素分泌.
- 蒂尔泽帕提德还增强了人类小岛的葡萄糖和体静止素分泌.
结论:
- 蒂尔泽帕提德通过GIP和GLP-1受体刺激人类小岛激素的分泌.
- 双受体激素对提泽帕提德在人类代谢调节中的有效性至关重要.
- 受体强度的差异解释了对蒂尔泽帕提德的特定物种反应.
相关概念视频
Glucagon-like Receptor Agonists
370
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
370
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
Insulin: Biosynthesis, Chemistry, and Preparation
443
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
443
Insulin: Dosing Regimen and Adverse Effects
216
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
216


